VIVUS Inc. will appoint Thomas King as interim CEO after Seth H. Z. Fischer steps down as CEO and board member, effective Dec. 31.
King has served as a director of the company since May 24. He served as president, CEO and director of Alexza Pharmaceuticals Inc. from June 2003 to August 2016, and has been an independent biotechnology consultant since August 2016.
Fischer will serve as a strategic adviser to the company through 2018 to ensure a smooth transition and continued advancement of the company's strategic initiatives.
